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Postprandial leucine and insulin responses and
toxicological effects of a novel whey protein
hydrolysate-based supplement in rats
Ryan G Toedebusch1, Thomas E Childs1, Shari R Hamilton2, Jan R Crowley3,4,
Frank W Booth1,5,6,7 and Michael D Roberts1*
Abstract
The purpose of this study was: aim 1) compare insulin and leucine serum responses after feeding a novel hydrolyzed
whey protein (WPH)-based supplement versus a whey protein isolate (WPI) in rats during the post-absorptive state, and
aim 2) to perform a thorough toxicological analysis on rats that consume different doses of the novel WPH-based
supplement over a 30-day period. In male Wistar rats (~250 g, n= 40), serum insulin and leucine concentrations were
quantified up to 120 min after one human equivalent dose of a WPI or the WPH-based supplement. In a second cohort
of rats (~250 g, n = 20), we examined serum/blood and liver/kidney histopathological markers after 30 days of feeding
low (1human equivalent dose), medium (3 doses) and high (6 doses) amounts of the WPH-based supplement. In aim 1,
higher leucine levels existed at 15 min after WPH vs. WPI ingestion (p= 0.04) followed by higher insulin concentrations at
60 min (p=0.002). In aim 2, liver and kidney histopathology/toxicology markers were not different 30 days after feeding
with low, medium, high dose WPH-based supplementation or water only. There were no between-condition differences
in body fat or lean mass or circulating clinical chemistry markers following the 30-day feeding intervention in aim 2. In
comparison to WPI, acute ingestion of a novel WPH-based supplement resulted in a higher transient leucine response
with a sequential increase in insulin. Furthermore, chronic ingestion of the tested whey protein hydrolysate supplement
appears safe.
Keywords: Diet, Leucine, Whey hydrolysate
Introduction
More than 150 million US residents consume dietary
supplements and many of those are products including
whey protein, creatine, and branched-chain amino acids
(BCAAs) [1]. Of the numerous marketed dietary supple-
ments, it is well known that whey protein supplementa-
tion augments resistance training adaptations [2].
Moreover, recent evidence suggests that the consump-
tion of whey protein elicits the greatest appearance of
essential amino acids and insulin and is thus the seem-
ingly most influential known protein source capable of
augmenting muscle anabolism [2–4]. Whey protein is
commercially categorized by concentration or by degree
of hydrolysate [5]. Whey protein concentrate (WPC)
may contain 29% to 89% total protein by volume, with
the remaining kcal coming from carbohydrates and
lipids, whereas whey protein isolate (WPI) composition
typically exceeds 90% total protein by volume [5]. WPH
is enzymatically hydrolyzed in order to obtain smaller
peptide fractions from its parent WPC or WPI source
and is thought to undergo more rapid gastrointestinal
absorption kinetics thus potentially improving amino
acid bioavailability. In support of this hypothesis, data
from Tang et al. [3] indicate that circulating leucine
levels were greater with ingestion of WPH versus soy or
casein at 30 minutes post ingestion in humans. Power
et al. [6] studied the serum insulin, phenylalanine and
total branched chain amino acid responses of ingesting
45 g of WPI or WPH after an overnight fast in humans.
Of the measured variables, these authors reported that
WPH elicited a statistically greater phenylalanine
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response compared to WPI [6]. Thus, there is still con-
flicting evidence as to whether or not WPH elicits a
more favorable serum anabolic response (i.e., greater in-
sulin and leucine values) relative to other whey protein
forms. Furthermore, limited evidence to our knowledge
has compared the postprandial effects that exist between
a whey protein isolate relative to a hydrolyzed whey pro-
tein derived from WPI [7]. Data comparing the effects of
different protein sources on serum amino acid and hor-
mone concentrations typically examine these phenom-
ena after overnight fasting period, which is not
applicable to those who consume supplemental protein
between meals. Lockwood et al. [8] studied the effects of
ingesting 60 g/day of WPH versus two different whey
protein concentrate supplements on body composition
after 8 weeks of progressive resistance training. The
authors discovered that all three protein forms similarly
affected total body muscle mass, strength, anaerobic en-
durance and blood lipids. However, the authors did not
analyze the acute feeding serum responses [8]. There-
fore, while WPH may elicit transient increases in circu-
lating leucine and insulin relative to other protein
sources, data is lacking with regard to how a WPH-
based supplement affects these variables in the post-
absorptive state.
Clarity is also warranted with regard to whether or not
weeks-to-months of whey protein supplementation yield
adverse health effects (i.e., kidney and/or liver damage).
Large-scale human studies have demonstrated that
higher protein intakes seemingly exert no adverse effects
on markers of renal or liver function [9,10]. There are,
however, equivocal safety concerns brought about
through the internet and media regarding the prolonged
effects of consuming copious amounts of dietary protein
whether it is through high protein foods or protein sup-
plements [11]. Likewise, there is the imminent possibility
that whey protein supplement users disregard and super-
sede the recommended dosages and combine whey with
other dietary supplement ingredients. Therefore, mul-
tiple dosages of protein supplements should be thor-
oughly investigated for safety of consumption.
Animal models offer a variety of advantages compared
to humans to study how mammals physiologically cope
with nutritional interventions. Specifically, animals’ diets
can be tightly regulated, multiple tissues can be dissected
and analyzed, and supplement adherence can be assured.
Therefore, the purpose of the current study was two-
fold: aim 1) to use a rat model to compare the post-
prandial insulin and leucine responses between a novel
WPH-based supplement versus a WPI powder in rats
that were in the post-absorptive state, and aim 2) to per-
form a thorough toxicological analysis on rats that were
fed low, medium, and high doses of the novel WPH-
based supplement over a 30-day period in order to
examine the safety of chronically consuming this protein
source. We hypothesized that the tested WPH-based sup-
plement would exhibit a superior insulin response when
compared to the insulin response of WPI. Likewise, we
hypothesized that leucine and insulin responses to the
WPH-based protein would be superior to WPI based upon
previous literature suggesting that the hydrolysis process
potentially increases the digestibility of WPH [7]. Finally,
we hypothesized that the supplement would not elicit
adverse health effects on the measured health parameters
on rats following a 30-day supplementation period.
Materials and Methods
Animals and experimental protocols
Male Wistar rats were obtained from Charles River La-
boratory weighing 175–200 g. Rats were between 45–48
days of age when received. They were allowed 7 days to
acclimatize to new housing and were maintained on a
12/12-h light/dark cycle, with food (Purinalab 5008
standard chow: 27% protein, 17% fat, 56% carbohydrates)
provided ad libitum until the experimental testing days
described below. Rats were received in 2 cohorts; the
first (n = 36) was used to examine circulating post-gavage
insulin and leucine responses between one human
equivalent dose (low dose) of WPI and the tested (low
dose) WPH-based supplement and the second (n = 20)
was used to study how 30 days of feeding a low dose
(1.1 g/d, or 1 human equivalent dose), medium dose (3.4
g/d, 3 human eq. doses), high dose (6.8 g/d, 6 human eq.
doses) of the WPH-based supplement affected toxico-
logical variables. The ingredients for each dose are
defined in the next section. The experimental protocol
was approved by the Institutional Animal Care and Use
Committee of The University of Missouri-Columbia.
Nutritional supplement information
The WPH-based supplement (Scivation, Inc) contains
the following active ingredients: Whey protein isolate
(Glanbia Nutritionals, Inc), extensively hydrolyzed whey
protein concentrate (32 degree of hydrolysis; average
molecular weight = 1.57 Daltons; Carbery), leucine pep-
tides (Glanbia Nutritionals, Inc), creatine monohydrate
(AlzChem Trostberg GmbH), patent-pending blend of
L-citrulline, L-lysine, vitamin C and folic acid (Genysis
Nutrition Labs), medium chain triglycerides, beet root
extract, and Rhodiola rosea root extract. One human
equivalent dose (low dose) of 33 g was set at 1.1 g for
rats weighing ~250 g. Major ingredients per 1 serving
size or dose (human: 33 g, rat: 1.1 g) of the WPH-
based supplement were then:
Energy! human: 110 kcal, rat: 3.67 kcal;
Total fat! human: 1.5 g, rat: 0.05 g;
Total carbohydrate! human: 3 g, rat: 0.1 g;
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Total protein! human 20 g, rat: 0.67 g;
Total leucine! human: 3.6 g, rat 0.12 g; and
Creatine! human: 2.5 g, rat 0.08 g.
The WPI powder (Mullins Whey Inc) used to compare
the serum leucine and insulin responses in aim 1 was
92% protein dry weight basis and contained 2.58 g leu-
cine per 33 g human serving (0.09 g per rat serving).
Note that rat dosaging was performed per the methods
of Reagan-Shaw et al. [12] whereby body surface area was
taken into account in order to administer a human
equivalent dose to rats for aim 1 as well as multiple doses
for aim 2.
Circulating post-prandial insulin- and leucine-response
profile of WPI versus the WPH-based supplement
On the morning of testing, male Wistar rats (Charles
Rivers Laboratories) aged 52–55 days (~250-300 g) had
food removed at the beginning of the light cycle. Three
hours later, each rat was gavage-fed a low dose (as
above) of either WPI or the WPH-based supplement
under light isoflurane anesthesia. The control condition
(n = 4) was sacrificed without gavage-feeding in order to
provide a baseline comparison point for fasting leucine
and insulin values. Rats that were gavage-fed were subse-
quently sacrificed under CO2 gas at 15 (WPH n= 6,
WPI n = 6), 30 (WPH n=4, WPI n = 4), 60 (WPH n=4,
WPI n = 4) and 120 (WPH n= 4, WPI n = 4) minutes
post gavage-feeding. A heart puncture using a 22-gauge
needle was performed to collect whole blood into serum
separator tubes and was subsequently centrifuged at
1300 rpm for 10 minutes in order to obtain serum. Of
note, all of the aforementioned gavage-feedings took
place between 1000–1600 hours.
Serum leucine concentrations were quantified using
gas chromatography-electron impact-mass spectrometry
(Agilent Technologies 6890 N capillary GC and 5973
Network Mass Selection Detector, Foster City, CA,
U.S.A.) at the Washington University Biomedical Mass
Spectrometry Research Resource. In brief, d3-leucine
(10 nmol) was added as an internal standard to 100 μL
serum. Serum amino acids were chemically converted to
their trimethylsilyl form using N,O-Bis(trimethylsilyl)tri-
fluoroacetamide + 10% Trimethychlorosilane (BSTFA+
10% TMCS, Regis, Morton Grove, IL), and selected ion
intensities for mass/charge 158 (natural Leu) and 161
(d3-Leu) were monitored. Serum insulin was analyzed
using an enzyme-linked immunosorbant assay specific
for rat species according to manufacturer’s protocol
(Millipore, Saint Charles, MO).
Toxicology assessment of chronic WPH supplementation
The potential toxocologic effects of a low dose, medium
dose, high dose of the WPH-based supplement as well
as tap water only was examined over a 30-day period.
The water only and low dose conditions required only
one gavage feeding per day. The medium and high dose
conditions required two and four gavage feedings per
day, respectively, in order to: a) administer the required
amount of protein to each rat, and b) to remain within
the guidelines (1 ml/100 g) for stomach distension.
Doses were recalculated per the aforementioned meth-
ods of Reagan-Shaw et al. [12] on a weekly basis during
the 30-day feeding experiment in order to accommodate
for rat growth from week to week.
Body composition using dual x-ray absorptiometry
(DXA, Hologic QDR-1000/w) calibrated for small ani-
mals was performed on this cohort of animals after 7
days and 30 days of feeding in order to track alterations
in body composition. Note that during this procedure,
animals were placed under light isoflurane anesthesia so
that the body scans could be performed.
Following the 30-day feeding schedule, animals were
sacrificed under CO2 gas and blood and tissue samples
were collected. Blood samples were obtained by cardiac
puncture at sacrifice and the blood was collected in lithium
heparin tubes. A complete blood count (CBC) was per-
formed on whole blood using an automated hematology
instrument (Hemavet 940FS, Drew Scientific, Dallas, TX).
After completion of the CBC, the blood was centrifuged at
5,000 g for 5 minutes to separate the plasma. The plasma
was harvested and a clinical biochemistry profile was per-
formed on the plasma using an automated chemistry
analyzer (AU640, Beckman-Coulter, Brea, CA) by Research
Animal Diagnostics Laboratory (RADIL; Columbia, MO).
For tissue histology, a section of the left lateral and
right medial liver lobes and both kidneys were collected,
fixed overnight in 10% formalin and embedded in paraf-
fin for histopathologic evaluation. Tissue sections were
stained with hematoxylin/eosin and were examined for
lesions by a veterinary pathologist specializing in rodent
histopathology who was blinded to treatment status at
RADIL. The body weight was recorded just after euthan-
asia and before bleeding, while heart and brain weights
were measured after bleeding.
Statistics
For aim 1, a two-way analysis of variance with Bonfer-
roni corrections was performed to compare circulating
leucine and insulin values in each postprandial rat con-
dition to rats that were 3-h fasted. For aim 2, Chi-
squared tests were performed in order to examine pro-
portion differences in animals in each condition that
presented signs of liver or kidney damage. One-way
ANOVAs were performed for each serum/whole blood
variable. For tracking changes in body composition vari-
ables, a two-way ANOVA (dose x time) was performed.
Unless otherwise stated in figures and tables, all data
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were expressed as means ± standard error values and sig-
nificance was set at p< 0.05.
Results
Post prandial serum leucine and insulin differences
between WPI and WPH
Figure 1A shows the leucine responses to the WPI and
WPH-based supplement relative to rats that were not
gavage-fed. In the WPI condition, serum leucine did not
statistically increase relative to the control rats that were
not gavage-fed. In contrast, WPH significantly increased
at 15-min post-ingestion relative to the unfed control
rats (p = 0.01). Importantly, a significant difference in cir-
culating leucine at 15 minutes post-WPH gavage existed
relative to 15 minutes post WPI-gavage (p = 0.04), but
not at other time points.
Figure 1B outlines the insulin responses to the WPI
and WPH-based supplement. For post-WPI gavage,
relative to the control rats that were not gavage-fed, no
significant increases occurred in serum insulin at 60 min-
utes, and 120 minutes, although there tended to be an in-
crease at 30 minutes post-gavage (p = 0.09). For post-
WPH gavage, relative to the control rats that were not
gavage-fed, a significant increase occurred in serum insu-
lin 60 minutes post-WPH gavage (p = 0.01), while there
were no significant increases in serum insulin at 30 min-
utes and 120 minutes (p> 0.05). Comparing the insulino-
genic responses of both protein sources against one
another at each time point importantly revealed that the
WPH-based supplement elicited a significantly greater
increase in insulin relative to WPI 60 minutes post-
gavage (p = 0.001).
Body composition and food intakes following 30 days of
feeding with different doses of the WPH-based supplement
When comparing the low-dose WPH, medium-dose
WPH, high-dose WPH, and water only, DXA analysis
demonstrated that there were no significant between-
condition differences from 7 days to 30 days in fat mass
Figure 1 Circulating postprandial leucine (A) and insulin (B)
responses of a WPH-based supplement versus WPI. Inset figures
represent postprandial areas under the curve (AUCs) of each
condition. All data are presented as mean± SE; n = 4–6 rats per time
point. Abbreviations/symbols: †=greater serum value than 3-h
fasting concentrations for the respective supplement; * =WPH>WPI
at a postprandial time point (p< 0.05).
Figure 2 Changes in DXA fat mass (A) and DXA lean mass (B)
from days 7 to 30 of daily gavage feeding 1 human equivalent
dose (1.1 g/d, ‘low’), 3 human equivalent doses (3.4 g/d,
‘medium’), and 6 human equivalent doses (6.8 g/d, ‘high’) of
the WPH-based supplement as well as water only (‘water’). All
data are presented as mean± SE and % changes from day 7 to day
30 are presented above each bar graph. No between-condition
differences were detected.
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(dose x time interaction p = 0.90; Figure 2). Similarly,
there were no between-condition differences in total
lean body mass (dose x time interaction p = 0.99) when
comparing the low-dose WPH, medium-dose WPH,
high-dose WPH, and water only (Figure 2).
As expected, progressive increases in the average
amount of protein consumed per day were present from
low to medium to high dosages (p< 0.05, Figure 3A).
Interestingly, there was also a significant difference be-
tween total energy consumed between WPH-based sup-
plement conditions with the high dose exhibiting a
significantly lower amount of food intake relative to the
low-dose (p< 0.05, Figure 3B) and water only condition
(p< 0.01).
Liver and kidney histopathology and serum clinical
chemistry profiles
Histopathological assays conducted on the liver and kid-
neys after 30 days of low dose, medium dose or high
dosages of the WPH-based supplement feeding showed
no adverse effects on clinical pathology markers relative
to water only feeding (Table 1). Interestingly, the propor-
tion of rats fed water for 30 days (4/5 rats) presented
significantly more >21 hepatocellular mitoses counts
(representative of potential liver damage) relative to rats
in the low (0%), medium (0%) and high WPH-based sup-
plement conditions (0%, X2 p = 0.001).
There were no significant differences in serum clinical
chemistry profiles between the 4 conditions (Table 2,
p> 0.05). Finally, there were no significant differences
in brain, heart, and whole body weights between the
4 conditions (Table 2, p> 0.05).
Discussion
Our data suggest that the tested WPH-based supple-
ment: a) exerted a transient rise in post-prandial leucine
and a subsequent insulin rise relative to WPI during a
post-absorptive (not fasted) state at the low dose; and b)
did not adversely affect markers of kidney, liver, and or
other health markers after a 30-day feeding period, while
decreasing food intakes in a dose-dependent fashion.
Together, these data regarding serum responses to the
tested WPH-based supplement can be considered to be
a promising lead for future experiments, which would
aim to continue examining the physiological effects that
WPH-based protein sources exhibit on other tissues
such as skeletal muscle and adipose tissue.
It has been shown that extracellular leucine availability,
with or without exercise, increases muscle protein syn-
thesis rates [3,14–17]. Likewise, the insulinogenic effects
of whey have been posited to potentially aid in augment-
ing muscle protein synthesis in an mTORC1-dependent
fashion independent of intramuscular mRNA expression
patterns [18], although this effect has been suggested to
be more permissive rather than stimulatory [14]. In
agreement with previous evidence, our data demon-
strates that WPH has been shown to be insulinogenic at
one hour following feeding in humans [3], albeit their
data was collected after an overnight fast. The mechan-
ism whereby whey elicits its superior insulinogenic
effects relative to other protein sources may be related to
unidentified bioactive peptides and/or its amino acid
profile; specifically arginine [19]. However, both protein
sources in our study possessed nearly similar amounts of
arginine (WPH-based supplement: 470 mg per human
serving, WPI = 510 mg). Nonetheless, our data suggests
that WPH may be superiorly insulinogenic relative to an
undigested whey protein source; an effect which we
speculate could be due either: a) its superior effect in
stimulating the transient increase in postprandial serum
leucine given that leucine has been shown to stimulate
insulin secretion [20], or b) the presence of unidentified
bioactive peptides that occur due to the hydrolysis
Figure 3 Average daily protein (‘PRO/d’, A) and kilocalorie
(‘kcal/d’, B) intake over the 30-day daily gavage feeding of 1
human equivalent dose (1.1 g/d, ‘low’), 3 human equivalent
doses (3.4 g/d, ‘medium’), and 6 human equivalent doses (6.8
g/d, ‘high’) of the WPH-based supplement as well as water only
(‘water’). All data are presented as mean± SE and daily averages are
presented numerically above each bar. As expected, average protein
intakes over the 30-day intervention (subfigure A) were as follows:
high>medium> low=water (p< 0.01 denoted by different letters
above each bar). Interestingly, energy intakes were significantly
lower in the high condition relative to the low and water conditions
(p-values presented above bars).
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process which stimulate pancreatic insulin secretion. In
regards to the later, Morifuji et al. [21] have determined
that dipeptides from WPH stimulate muscle glucose up-
take via PI3-kinase and protein kinase C (PKC) pathways.
Therefore, existing evidence in the literature, demon-
strates that WPH-based peptides exhibit significant
physiological effects on the pancreas warrants future re-
search into elucidating mechanisms that drive these
phenomena.
As mentioned previously, WPH has been shown to
elicit a transient leucine spike in the serum, although
this effect has only been shown under fasting condi-
tions and when comparing WPH to casein and soy
[3]; of note WPI and WPH have been examined for
branched chain amino acid responses, but not leucine
responses explicitly [7]. Fasting rats for 12 hours prior
to feeding them a high-protein test meal yielded serum
leucine concentrations that were 60% lower than the
rats in our study after 3 hours of food removal [22]
which implies that our animals were in a post-absorptive
(not fasted) state. However, we chose to examine the
leucine responses between the WPH-based versus WPI
after a 3-h food withdrawal with the notion that
humans would likely consume the whey protein-based
supplement prior to or following an exercise bout
within 3–6 hours of consuming a meal, as most
humans eat throughout the wake cycle. Therefore, this
is the first report to our knowledge demonstrating that
subjects in the post-absorptive state exhibit greater
leucine and subsequent insulin responses when
Table 1 Dose-dependent effects of WPH feeding for 30 days on liver and kidney histopathology markers
Variable water (n = 5) low (n= 5) medium (n = 5) high (n= 5)
Kidney histopathology
basophilia of tubules in corticomedullary junction 0/5 1/5 0/5 1/5
moderate unilateral hydronephrosis 0/5 0/5 0/5 1/5
large focal tubular regeneration with lymphocytes 0/5 0/5 1/5 0/5
focal tubular mineralization 0/5 1/5 0/5 0/5
focal perivascular lymphoid infiltrate 1/5 0/5 0/5 0/5
1-2 proteinaceous tubular casts 3/5 0/5 0/5 1/5
tubular regeneration with interstitial lymphocytes 1/5 0/5 0/5 1/5
focal tubular regeneration 2/5 0/5 2/5 1/5
Liver histopathology
moderate multifocal centrilobular lipidosis 1/5 3/5 2/5 1/5
mild multifocal centrilobular lipidosis 3/5 2/5 2/5 3/5
few mild foci lipidosis 1/5 0/5 1/5 1/5
1-2 multinucleated giant cells 1/5 1/5 1/5 1/5
focal granulopoeisis 0/5 1/5 0/5 0/5
focal erythropoeisis 3/5 0/5 0/5 1/5
>21 hepatocellular mitoses 4/5† 0/5 0/5 0/5
11-20 hepatocellular mitoses 0/5 2/5 1/5 0/5
1-10 hepatocellular mitoses 1/5 3/5 4/5 1/5
6-10 apoptotic cells 3/5 0/5 1/5 0/5
1-5 apoptotic cells 2/5 5/5 3/5 3/5
6-10 microgranulomas 2/5 0/5 1/5 0/5
1-5 microgranulomas 3/5 2/5 3/5 3/5
Effects of 30 days of daily gavage feeding 1 human equivalent dose (1.1 g/d, ‘low’), 3 human equivalent doses (3.4 g/d, ‘medium’), and 6 human equivalent doses
(6.8 g/d, ‘high’) of the WPH-based supplement as well as water only (‘water’) on markers of kidney and liver damage.
Liver apoptotic cell and microgranuloma counts represent potential liver injury/damage; hepatocellular mitoses and focal granuloposis/erythropoesis counts
represent potential liver regeneration after injury; liver lipidosis counts represent the development of fatty liver.
Kidney histopathlogy definitions [derived from reference Guyton and Hall [13]:
Basophilia of tubules in corticomedullary junction counts represent potential nephron damage; moderate unilateral hydronephrosis represent excessive dilation of
the kidneys and potential decrement in kidney function; large focal tubular regeneration with lymphocytes counts represent potential kidney damage and
toxicity; focal tubular mineralization counts represent potential tubular damage; focal perivascular lymphoid infiltrate counts represent potential kidney damage
and toxicity.
Liver histopathology definitions (derived from reference Guyton and Hall [13]):
Symbols: † indicates proportion of observations with water is significantly higher than observations in different treatment conditions as determined by a
Chi-square test (p = 0.001).
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Table 2 Dose-dependent effects of WPH feeding for 30 days on blood and other health markers
Variable p-value between conditions water (n = 5) low (n= 5) medium (n= 5) high (n= 5)
Serum markers
Triglycerides (mg/dL) p = 0.60 184 ± 28 169± 18 187 ± 13 153 ± 14
Glucose (mg/dL) p = 0.32 183 ± 12 154± 11 187 ± 17 167 ± 14
Urea Nitrogen (mg/dL) p = 0.45 25 ± 1 24± 1 26± 1 24± 2
Creatinine (mg/dL) p = 0.25 0.41 ± 0.01 0.39 ± 0.01 0.44 ± 0.03 0.38 ± 0.02
Sodium (mmol/L) p = 0.33 145± 1 147 ± 1 144 ± 1 146± 1
Potassium (mmol/L) p = 0.20 6.4 ± 1 5.8 ± 0 6.9 ± 1 5.1 ± 0
Chloride (mmol/L) p = 0.59 99 ± 0 98± 1 98± 0 99± 0
Total Protein (g/dL) p = 0.17 6.9 ± 0.1 6.7 ± 0.1 6.7 ± 0.1 6.5 ± 0.0
Albumin (g/dL) p = 0.26 3.5 ± 0.0 3.4 ± 0.0 3.4 ± 0.1 3.4 ± 0.1
Calcium (mg/dL) p = 0.06 12.8 ± 0.1 12.5 ± 0.2 12.4 ± 0.3 12.0 ± 0.1
Phosphorus (mg/dL) p = 0.40 10.8 ± 0.5 10.6 ± 0.6 11.7 ± 0.5 10.5 ± 0.4
Cholesterol (mg/dL) p = 0.34 82 ± 10 64 ± 3 68± 7 74± 7
Total Bilirubin (mg/dL) p = 0.08 0.10 ± 0.0 0.10 ± 0.0 0.14 ± 0.0 0.10 ± 0.0
ALT (U/L) p = 0.68 239 ± 43 254± 54 298 ± 34 234 ± 27
ALP (U/L) p = 0.52 186 ± 16 179± 11 161 ± 4 165 ± 18
GGT (U/L) p =N/A <3 <3 <3 <3
Total CO2 (mmol/L) p = 0.14 33 ± 1 37± 2 32± 2 33 ± 1
Whole blood markers
WBC (x10³/μL) p = 0.88 12.5 ± 0.9 11.3 ± 1.2 12.0 ± 1.2 11.8 ± 0.5
Seg. Neutro (x10³/μL) p = 0.85 1.7 ± 0.2 1.7 ± 0.6 1.3 ± 0.3 1.8 ± 0.3
Band Neutro (x10³/μL) p = 0.99 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
Lymphocytes (x10³/μL) p = 0.74 10.7 ± 0.9 9.6 ± 0.7 10.5 ± 1.0 9.8 ± 0.5
Monocytes (x10³/μL) p = 0.32 0.07 ± 0.03 0.00 ± 0.00 0.06 ± 0.04 0.05 ± 0.03
Eosinophils (x10³/μL) p = 0.92 0.12 ± 0.09 0.09 ± 0.07 0.09 ± 0.05 0.16 ± 0.10
Basophils (x10³/μL) p = 0.99 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
RBC (M/μL) p = 0.47 8.5 ± 0.1 8.4 ± 0.1 8.6 ± 0.2 8.7 ± 0.1
Hemoglobin (g/dL) p = 0.08 16.1 ± 0.3 16.9 ± 0.3 16.3 ± 0.2 16.8 ± 0.2
Hematocrit (%) p = 0.75 52.7 ± 1.1 53.4 ± 0.9 52.7 ± 1.1 53.8 ± 0.5
MCV (fL) p = 0.29 61.7 ± 0.8 63.5 ± 0.7 61.5 ± 0.9 61.8 ± 0.7
MCH (pg) p = 0.01 18.8 ± 0.3a 20.1 ± 0.2b 19.1 ± 0.3a 19.3 ± 0.2c
MCHC (g/dL) p = 0.08 30.5 ± 0.3 31.7 ± 0.2 31.1 ± 0.5 31.2 ± 0.1
Cell Volume (%) p = 0.19 49.8 ± 0.9 51.4 ± 0.4 49.8 ± 0.6 50.6 ± 0.2
Platelets (x10³/μL) p =N/A Clumps Clumps Clumps Clumps
Hemolysis p =N/A Clear Clear Clear Clear
MPV (fL) p = 0.38 6.7 ± 0.1 6.3 ± 0.2 6.7 ± 0.3 6.5 ± 0.2
Post necropsy organ and body weights
Brain (g) p = 0.57 2.03 ± 0.03 2.08 ± 0.04 2.08 ± 0.02 2.04 ± 0.06
Heart (g) p = 0.88 1.40 ± 0.07 1.37 ± 0.04 1.35 ± 0.04 1.40 ± 0.05
Whole Body (g) p = 0.69 439 ± 14 422 ± 9 419 ± 2 422 ± 20
Effects of 30 days of daily gavage feeding 1 human equivalent dose (1.1 g/d, ‘low’), 3 human equivalent doses (3.4 g/d, ‘medium’), and 6 human equivalent doses
(6.8 g/d, ‘high’) of the WPH-based supplement as well as water only (‘water’) on clinical chemistry serum and whole blood markers.
Abbreviations (definitions): ALT= alanine aminotransferase (liver enzyme); ALP= alkaline phosphatase (liver and bone enzyme); GGT=gamma-glutamyl
transpeptidase (liver enzyme); WBC=white blood cells; Seg. Neutro. = segmented neutrophils; RBC= red blood cells; MCV=mean corpuscular volume (measure of
RBC size); MCH=mean corpuscular hemoglobin (average hemoglobin per red blood cell); MCHC=mean corpuscular hemoglobin concentration (average
hemoglobin concentration per red blood cell); MPV=mean platelet volume (average size of platelets in whole blood).
Note that the ‘low’ condition presented significantly greater MCH content relative to the water and medium conditions (denoted by letter superscripts, p< 0.05).
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ingesting a hydrolyzed whey protein source versus a
native whey protein isolate.
We also report that 30 days of chronic supplementa-
tion with a WPH-based supplement in rodents aged 62
days old when study began: a) causes no apparent ad-
verse health effects on the kidneys and/or liver, b) does
not affect brain and/or heart weights, c) does not affect
circulating clinical chemistry and whole blood markers,
and d) does not alter body composition. As mentioned
previously, studies in healthy humans have demonstrated
that higher protein intakes seemingly exert no adverse
effects on markers of renal or liver function [9,10]. Re-
sistance training studies have also determined that in-
creasing protein intakes for two months did not
negatively impact serum clinical chemistry markers
related to kidney and liver damage [23,24]. However,
concern still exists in the medical literature regarding
the potential negative effects that protein supplementa-
tion exerts on liver [11,25] and kidney physiology
[25,26]. While limited data exists on the safety of
chronic whey protein supplementation, little data to our
knowledge has utilized a rodent model whereby liver
and kidney tissues were morphologically examined for
lesions following chronic feeding. One recent study [27]
did determine that 18 days of WPI consumption offset
liver toxicity caused by the concomitant administration
of a pro-oxidant agent (dimethylnitrosamine). Interest-
ingly, we determined that only the water condition pre-
sented a greater incidence of liver damage (> 21
hepatocellular mitoses) relative to the WPH-supplemen-
ted conditions. We speculate that WPH or whey protein
supplementation in general supplementation could in-
deed be hepatoprotective. Of note, the WPH supplement
contained Rhodiola rosea extract which is a well-known
adaptogen that confers hepatoprotective (i.e., antioxidant
and antilipidemic) effects in db/db mice [28]. Whether it
is the WPH fraction and/or the Rhodiola rosea extract
in the WPH-based supplement, we conclude that the
WPH-based supplement used in our study does not ex-
acerbate liver damage when administered in very high
doses and could, instead, confer hepatoprotective effects.
Contrary to the one referenced study examining the
effects of whey protein on liver histopathology markers
in rodents [27], our study is seemingly the first to sug-
gest that 30 days of feeding a range of WPH-based pro-
tein dosages to rats does not negatively impact kidney
damage/toxicology markers and/or circulating markers
of kidney function (i.e., creatinine and blood urea nitro-
gen). Rats in the high dose condition consuming 6
human equivalent doses per day (would be equivalent to
an additional 120 g of protein in humans) increased
daily protein intakes up to 21.7 g/kg/day. Additionally,
30-days of creatine feeding present within the WPH-
based supplement did not adversely affect the examined
health markers; for the high dose condition this would
be equivalent to a human consuming 15 g/d of creatine.
Therefore, our 30-day study is in agreement with other
literature which continues to refute speculation that
whey protein [9,10] and/or creatine supplementation
[29] negatively impacts kidney function and/or elicits
kidney damage in animals that do not possess pre-
existing kidney issues.
Interestingly, animals that were gavage-fed three and
six human equivalent doses per day of the WPH-based
supplement for 30 days consumed less total kilocalories
per day relative to animals that consumed one human-
equivalent dose and water over this time frame. Multiple
studies have established that whey protein may exert sa-
tiating effects and reduce adiposity in rats [30,31]. In
explaining this effect, authors from the later study
propose that whey-derived proteins do elicit a satiating
effect through the enhanced secretion of gut neuropep-
tides including cholecystokinin (CCK) or glucagon-like
peptide-1 (GLP-1). Thus, this effect might have been
observed in our study although examining circulating
CCK and GLP-1 was beyond the scope of our investiga-
tion. With regard to body composition alterations, how-
ever, the feeding intervention in our study did not
confer changes in body fat in the protein supplemented
conditions. Likewise, the feeding intervention did not in-
crease DXA lean body mass which has been demon-
strated in the aforementioned rodent study that
chronically fed rats whey protein over a 25-day period
[31]. However, that Pichon et al. [31] used dissection
methods to assess body composition whereas our DEXA
method may introduce a larger degree of error which
could have obscured our findings. Furthermore, we can-
not rule out the hypothesis that consuming higher pro-
tein diets over longer periods (i.e., years to decades in
humans) reduces adiposity and enhances and/or main-
tains muscle mass during maturation and subsequent
aging in humans, respectively.
It is also noteworthy mentioning that there are limita-
tions to the current study. First, rodents were examined
instead of humans with regards to studying leucine, in-
sulin, and toxicological responses to these whey protein
sources. It should be noted, however, that rats and
humans seem to respond similarly to whey protein as it
has been shown to increase circulating leucine and mar-
kers of muscle protein synthesis following exercise in
both species [3,32]. Thus, we hypothesize that human
responses will likely be similar when examining the
physiological effects of WPH versus WPI supplements.
With regard to the current toxicology study, it should be
noted that only 5 animals were examined per condition
over a 30-day feeding period. In parallel to our study,
however, there are other recent studies examining the
toxicological effects of other compounds which have
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similarly studied 6 animals per condition [33,34]. Creat-
ine monohydrate (equivalent to 2.5 g/dose for humans)
is also a major ingredient in the WPH-based supple-
ment. However, creatine monohydrate does not alter
glucose tolerance or insulin sensitivity and is not insuli-
nogenic nor does it affect circulating leucine concentra-
tions [35]. With regard to other major ingredients
present in the WPH-based supplement, L-citrulline has
not been shown to impact circulating insulin and/or leu-
cine levels [36], although vitamin C has been shown to
reduce insulin in type II diabetes patients over chronic
supplementation periods [37], and L-lysine may stimu-
late insulin secretion from pancreatic beta cells [38].
Therefore, beyond the active biopeptides that exist in
the WPH formulation, other ingredients may have influ-
enced the insulin response. Finally, while we examined
the postprandial circulating leucine response to a WPH-
based supplement versus WPI, it remains unknown as to
whether or not potential unknown biologically active
peptide fragments that occur during the whey hydrolysis
process spike in the bloodstream after feeding relative
to WPI [this aspect of food science is reviewed in
[39]. In this regard, future animal and/or human stud-
ies should pursue this exciting and unexplored nutra-
ceutical research area in order to determine if WPH
supplementation with exercise confer positive skeletal
muscle anabolic responses due to potential increases in
circulating bioactive peptide fragments relative to other
protein sources.
Conclusions
In summary, our rodent feeding model uniquely found
that the WPH-based supplement elicited greater transi-
ent leucine with a subsequent increased insulin response
relative to the WPI. Given these data in conjunction
with the recent data demonstrating that WPH may pos-
sess biologically active peptide fragments [5], it will be of
future interest to compare the anabolic effects of WPI-
versus WPH-based supplements surrounding resistance
training and/or the effect of WPH-based supplements in
persons with diminished insulin secretion. Our 30-day
feeding rodent model suggests that WPH-based supple-
ments are safe to consume for one month in rats and
may confer satiating effects which reduced total food in-
take, albeit the relatively short-term feeding study did
not unveil significant alterations in total fat mass be-
tween the administered dosages. In this regard, longer-
term human studies might be performed in order to
examine the potential weight regulatory effects that
WPH-based products (i.e., meal-replacement shakes)
may exhibit on overweight and obese populations.
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